Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Thrombin
    (2)
  • Endogenous Metabolite
    (1)
  • Factor Xa
    (1)
  • Interleukin
    (1)
  • P2Y Receptor
    (1)
  • Prostaglandin Receptor
    (1)
  • RSV
    (1)
  • SARS-CoV
    (1)
  • Others
    (4)
TargetMol | Tags By ResearchField
  • Cardiovascular System
    (3)
  • Infection
    (1)
  • Inflammation
    (1)
  • Metabolism
    (1)
  • Nervous System
    (1)
  • Others
    (1)
Filter
Search Result
Results for "

percutaneous

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    8
    TargetMol | All_Pathways
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Natural Products
    1
    TargetMol | Natural_Products
  • Research Areas
    1
    TargetMol | Research_Areas
Bivalirudin
Hirulog-1, BG-8967
T5519128270-60-0
Bivalirudin (BG-8967) is a reversible inhibitor of α- and ζ-thrombin (Kis = 2.56 and 1.84 nM, respectively), enzymes that exhibit high fibrinogen-clotting activities.
  • $29
In Stock
Size
QTY
TargetMol | Citations Cited
Prasugrel
PCR 4099, LY640315, CS-747
T0230150322-43-3
Prasugrel (CS-747) is a piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.
  • $37
In Stock
Size
QTY
Laurocapram
Tranzone, N-Lauryl caprolactam, N-Dodecylcaprolactam, N-0252, Azone
T2A250959227-89-3
Laurocapram (N-Lauryl caprolactam) is a percutaneous enhancer. Upon application to the skin, laurocapram interacts with lipids in the stratum corneum and may enhance the ability of the skin to absorb a hydrophilic chemical.
  • $29
In Stock
Size
QTY
trans-Cyclohexane-1,2-diol
trans-1,2-Cyclohexanediol
T47631460-57-7
trans-Cyclohexane-1,2-diol (trans-1,2-Cyclohexanediol) has a synergistic retardation effect on percutaneous absorption and penetration of metronidazole (MTZ).
  • $29
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Enoxaparin sodium
T22323679809-58-6
Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI)
  • $31
In Stock
Size
QTY
C16 Phytoceramide (t18:0/16:0)
T38180111149-09-8
C16 Phytoceramide (t18:0/16:0) is a phytoceramide, which is a family of sphingolipids found in the intestine, kidney, and extracellular spaces of the stratum corneum of the mammalian epidermis. C16 Phytoceramide (t18:0/16:0) is composed of a phytosphingosine backbone amine-linked to a C16 fatty acid chain. The levels of C16 phytoceramide (t18:0/16:0) increase following heat stress in S. cerevisiae. It has been used with other ceramides to create stratum corneum substitutes to study percutaneous penetration and psoriasis in vitro.
  • $276
Inquiry
Size
QTY
C24 Phytosphingosine (t18:0/24:0)
T3829134437-74-6
C24 Phytosphingosine (t18:0/24:0) is a phytoceramide, which is a family of sphingolipids found in the intestine, kidney, and extracellular spaces of the stratum corneum of the mammalian epidermis. C24 Phytosphingosine (t18:0/24:0) is composed of a phytosphingosine backbone amine-linked to a C24 fatty acid chain. It has been used with other ceramides to create stratum corneum substitutes to study percutaneous penetration and psoriasis in vitro. In a stratum corneum model of healthy skin, the incorporation of long-chain-containing phytoceramides, such as C24 phytosphingosine (t18:0/24:0), increases permeability of the membrane in comparison with incorporation of dihydroceramides.
  • $185
35 days
Size
QTY
Ciprostene (free base)
T6863981845-44-5
Ciprostene (free base) is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene was evaluated in clinical trials in patients with peripheral vascular disease. It was found to reduce restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty.
  • $2,120
8-10 weeks
Size
QTY